Absorption enhancement studies of clopidogrel hydrogen sulphate in rat everted gut sacs

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 4, 2012, Pages 541-552

  Lassoued, Mohamed Ali ^a   Sfar, Souad ^a   Bouraoui, Abderrahman ^a   Khemiss, Fathia ^b  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

clopidogrel; everted gut sac; P glycoprotein; solid dispersion; solubility

Indexed keywords

AURANTIIN; CLOPIDOGREL; DRUG CARRIER; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MACROGOL 6000; QUINIDINE; TARTARIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISPERSION; DRUG ABSORPTION; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG SOLUBILITY; EVERTED GUT SAC MODEL; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE ABSORPTION; JEJUNUM; MALE; NONHUMAN; RAT; SOLID DISPERSION; WATER TRANSPORT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FLAVANONES; INTESTINAL ABSORPTION; JEJUNUM; MALE; P-GLYCOPROTEIN; PLATELET AGGREGATION INHIBITORS; QUINIDINE; RATS; RATS, WISTAR; SOLUBILITY; TARTRATES; TICLOPIDINE;

EID: 84859101513     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01434.x     Document Type: Article

References (40)

1. Chillistone S, Hardman J,. Factors affecting drug absorption and distribution. Anaesth Intensive Care Med 2011; 12: 151-155.
2. Scherrmann JM,. Transporters in absorption, distribution and elimination. Chem Biodivers 2009; 6: 1933-1942.
3. Cuisset T, et al,. Clopidogrel resistance: what's new? Arch Cardiovasc Dis 2010; 103: 349-353.
4. Park KJ, et al,. Clinical, pharmacokinetic and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. Korean J Lab Med 2011; 31: 91-94.
5. Gachet C, Aleil B,. The inter-individual variability of the response to clopidogrel. Arch Mal Coeur Vaiss 2005; 98: 216-225.
6. Taubert D, et al,. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486-501. (Pubitemid 44767878)
7. Simon T, et al,. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
8. Ancrenaz V, et al,. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability. Curr Drug Metab 2010; 11: 667-677.
9. Clarke TA, Waskell LA,. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-59. (Pubitemid 36735258)
10. Streubel A, et al,. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol 2006; 6: 501-508. (Pubitemid 44340666)
11. Dahan A, Amidon GL,. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol 2009; 297: G371-G377.
12. Singh A, et al,. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Deliv 2011; 8: 1361-1378.
13. Ishikawa T, et al,. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 2004; 19: 1-14.
14. Linardi RL, Natalini CC,. Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodynamic of therapeutic drugs. Cienc Rural 2006; 36: 336-341.
15. Mouly S, Paine MF,. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599. (Pubitemid 37268274)
16. Kim RB,. Drugs as P-glycoprotein substrates, inhibitors and inducers. Drug Metab Rev 2002; 34: 47-54. (Pubitemid 34311087)
17. Föger F,. Strategies to overcome efflux pumps. In:, Bernkop-Schnürch A, ed. Oral Delivery of Macromolecular Drugs: Barriers, Strategies and Future Trends. New York: Springer Science and Business Media LLC, 2009: 123-136.
18. European Council. European Pharmacopeia, 5th edn. Strasbourg, France: Council of Europe, 2004.
19. Leonardi D, et al,. Development of prednisone:polyethylene glycol 6000 fast-release tablets from solid dispersions: solid-state characterization, dissolution behaviour, and formulation parameters. AAPS Pharm Sci Technol 2007; 8: E1-E8.
20. Lassoued MA, et al,. Comparative study of two in vitro methods for assessing drug absorption: Sartorius SM 16750 apparatus versus everted gut sac. J Pharm Pharm Sci 2011; 14: 117-127.
21. Patel V, et al,. Development of microemulsion for solubility enhancement of clopidogrel. Iran J Pharm Res 2010; 9: 327-334.
22. Khemiss F, et al,. Effect of in vitro exposure to Vibrio vulnificus on hydroelectrolytic transport and structural changes of sea bream (Sparus aurata L.) intestine. Fish Physiol Biochem 2009; 35: 541-549.
23. Moore JW, Flanner HH,. Mathematical comparison of dissolution profiles. Pharm Technol 1996; 20: 64-74. (Pubitemid 126450495)
24. El-Badry M, et al,. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in gelucire 50/13 and PEG 4000. Saudi Pharm J 2009; 17: 217-225.
25. Kolbe I, et al,. Preparation and characterization of clopidogrel/DIMEB complex. J Incl Phenom Macrocycl Chem 2002; 44: 183-184. (Pubitemid 38075688)
26. Vasconcelos T, et al,. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today 2007; 12: 1068-1075. (Pubitemid 350186132)
27. Bohets H, et al,. Strategies for absorption screening in drug discovery and development. Curr Top Med Chem 2001; 1: 367-383.
28. Wang J, et al,. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007; 3: 641-665. (Pubitemid 351320635)
29. Barthe L, et al,. The inproved everted gut sac: a simple method to study intestinal P-glycoprotein. Int J Pharm 1998; 173: 255-258.
30. Carreno-Gomez B, Duncan R,. Everted rat intestinal sacs: a new model for the quantification of P-glycoprotein mediated-efflux of anticancer agents. Anticancer Res 2000; 20: 3157-3161.
31. Arellano C,. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharm Sci 2007; 10: 26-36. (Pubitemid 46647804)
32. Khemiss F, et al,. Study of Grewia tenax fruit on iron absorption by everted gut sac. J Ethnopharmacol 2006; 103: 90-98.
33. Khemiss F, et al,. Aeromonas hydrophila disturbs water and electrolyte transport in Mugil cephalus L. intestine. Afr J Biotechnol 2008; 7: 373-380. (Pubitemid 351354580)
34. Tukker JJ,. In vitro methods for the assessment of permeability. In:, Dressman JB, Lennernas H, eds. Oral Drug Absorption: Prediction and Assessment. New York: Marcel Dekker, 2000: 51-72.
35. Choi JS, Han HK,. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Int J Pharm 2005; 305: 122-128.
36. Iida A, et al,. Improvement of intestinal absorption of P-glycoprotein substrate by d-tartaric acid. Drug Metab Pharmacokinet 2006; 21: 424-428.
37. Shen Q, et al,. Modulating effect of polyethylene glycol on intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. J Pharm Pharmacol 2008; 60: 1633-1641.
38. Chaud MV, et al,. Solid dispersions with hydrogenated castor oil increase solubility, dissolution rate and intestinal absorption of praziquantel. Braz J Pharm Sci 2010; 46: 473-481.
39. Hayashi M, Tomita M,. Mechanistic analysis for drug permeation through intestinal membrane. Drug Metab Pharmacokinet 2007; 22: 67-77.
40. Sababi M, et al,. The role of P-glycoprotein in limiting intestinal regional absorption of digoxin in rats. Eur J Pharm Sci 2001; 14: 21-27. (Pubitemid 32655411)